Sec declares form s-4 registration statement "effective" for proposed business combination of murphy canyon acquisition corp. with conduit pharmaceuticals limited

Special meeting of murphy canyon stockholders to vote on the proposed business combination scheduled for september 7, 2023 conduit is a disease agnostic life science company providing an efficient model for compound development led by a highly experienced team of pharmaceutical executives murphy canyon and conduit entered into a definitive business combination agreement dated november 8, 2022, as amended (the "business combination agreement") combined company expected to be named conduit pharmaceuticals inc. and listed on nasdaq in the third quarter of 2023 under the symbols "cdt" and "cdttw" san diego, ca / accesswire / august 16, 2023 / murphy canyon acquisition corp. (nasdaq:murf) or ("murphy canyon"), a blank-check special purpose acquisition company, is pleased to announce that its proxy statement/registration statement on form s-4 filed with the u.s. securities and exchange commission ("sec") on may 12, 2023, as amended (the "registration statement"), was declared effective by the sec on august 11, 2023. the registration statement was filed in connection with the proposed business combination between murphy canyon and conduit pharmaceuticals limited ("conduit") previously announced on november 8, 2022.
SQFT Ratings Summary
SQFT Quant Ranking